Cargando…

Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer

The aim of the present study was to observe the efficacy of neoadjuvant trastuzumab combined with docetaxel and carboplatin (TCH), and docetaxel, epirubicin and cyclophosphamide (TEC) chemotherapy in human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer. The total cohort of 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	CHEN, WEICAI, HE, JINSONG, SONG, SHUFEN, WANG, MIN, WU, HUISHENG, WANG, XIANMING
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356353/ https://www.ncbi.nlm.nih.gov/pubmed/25789069 http://dx.doi.org/10.3892/ol.2015.2912

Ejemplares similares

Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer
por: He, Jinsong, et al.
Publicado: (2011)

Efficacy and safety of TE/TEC/intensive paclitaxel neoadjuvant chemotherapy for the treatment of breast cancer
por: Liu, Yang, et al.
Publicado: (2019)

miRNA-411 acts as a potential tumor suppressor miRNA via the downregulation of specificity protein 1 in breast cancer
por: Guo, Liangfeng, et al.
Publicado: (2016)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
por: Lv, Zhi-Dong, et al.
Publicado: (2022)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
por: Li, Si, et al.
Publicado: (2018)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
por: Groheux, D, et al.
Publicado: (2013)

The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
por: Zhang, Wei, et al.
Publicado: (2017)

Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Wang, Huan, et al.
Publicado: (2020)

Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen
por: Zhu, Jiujun, et al.
Publicado: (2022)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer
por: Bayarmaa, Battseren, et al.
Publicado: (2019)

TEC Installation
por: CERN. Geneva. Audiovisual Unit
Publicado: (1989)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer
por: Li, Huiping, et al.
Publicado: (2016)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?
por: Wu, Juan, et al.
Publicado: (2019)

Efficacy of Neoadjuvant Single or Dual Anti-HER-2 Therapy Combined with Chemotherapy in Patients with HER-2-Positive Breast Cancer: A Single-Center Retrospective Study
por: He, Qian, et al.
Publicado: (2021)

HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review
por: Wang, Luo, et al.
Publicado: (2022)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
por: Arai, Roberto J., et al.
Publicado: (2018)

Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022)

Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis
por: He, Jinsong, et al.
Publicado: (2015)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
por: Lucas, Mairi W, et al.
Publicado: (2022)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
por: Tateishi, Kaho, et al.
Publicado: (2023)

PLLA-PEG-TCH-labeled bioactive molecule nanofibers for tissue engineering
por: Chen, Jun, et al.
Publicado: (2011)

Facile detection of mechanical forces across proteins in cells with STReTCh
por: Zhong, Brian L., et al.
Publicado: (2022)

Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis
por: He, Lin, et al.
Publicado: (2019)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI
por: Liu, Yongguang, et al.
Publicado: (2022)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
por: Tang, Lingfeng, et al.
Publicado: (2022)

Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Chantada-Vázquez, María del Pilar, et al.
Publicado: (2022)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress
por: Chen, Yushi, et al.
Publicado: (2023)

The Predictive Value of Pre-therapeutic Serum Gamma-glutamyl transferase in Efficacy and Adverse Reactions to Neoadjuvant Chemotherapy among Breast Cancer Patients
por: Sun, Lu, et al.
Publicado: (2020)

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
por: Ilie, Silvia Mihaela, et al.
Publicado: (2023)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
por: Kim, Hee Jeong, et al.
Publicado: (2020)

Characterization of CA-MRSA TCH1516 exposed to nafcillin in bacteriological and physiological media
por: Poudel, Saugat, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s2daif4fgkclfe13499037ta35